Saving Money: By reducing complications from chronic diseases, semaglutide could save the UK healthcare system approximately 1.68 billion by 2040
In a recent Medscape feature, experts including Dr
they were evolved to keep us alive in a dangerous world
Monami M, Iacomelli I, Marchionni N, Mannucci E (2010) Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
When these medications reduce the brain's reward response to food, some patients find that the dampening effect extends beyond eating
Clinical research continues to highlight how foundational behaviourssuch as increasing soluble and prebiotic fibres, prioritising protein at meals, including healthy fats, supporting a diverse microbiome, moving regularly and protecting sleepoperate synergistically to influence GLP-1 secretion and sensitivity